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GLP-1–Based Therapy for Diabetes: What
You Do Not Know Can Hurt You
A
ccording to the Oxford Dictionary of
Proverbs, the oldest written version
ofthesaying“Whatyoudon’tknow
can’t hurt you” comes from Petit Palace,
written in 1576 by G. Pettie: “So long as I
know it not, it hurteth mee not.”
InthisissueofDiabetesCare,Drucker
etal.(1)concludethatthesafetyproﬁleof
the newly available glucagon-like peptide
1 (GLP-1) class of drugs is favorable in
comparison to their beneﬁts as therapy,
and the class of drugs might be consid-
ered as next in line after metformin for
treatment for type 2 diabetes. The pur-
pose of this counterpoint is to suggest
such a conclusion is premature. History
has taught us that enthusiasm for new
classes of drugs, heavily promoted by the
pharmaceutical companies that market
them,canobscurethecautionthatshould
be exercised when the long-term conse-
quences are unknown. Of perhaps great-
est concern in the case of the GLP-1–
based drugs, including GLP-1 agonists
and dipeptidyl peptidase-4 (DPP-4) in-
hibitors, is preliminary evidence to sug-
gest the potential risks of asymptomatic
chronic pancreatitis and, with time, pan-
creatic cancer.
The GLP-1–related drugs arrived in
clinical practice with much fanfare and an-
ticipation. As summarized in the article by
Drucker et al., it is a class of drugs that has
potential beneﬁts in the treatment of type 2
diabetes. The concept of gut-related factors
that enhance glucose-mediated insulin se-
cretion, the incretin effect, has been recog-
nized for many years (2). Once it was
demonstrated that an intravenous infusion
ofGLP-1coulddecreasebloodglucosecon-
centrations in patients with type 2 diabetes,
the race was on to exploit the properties of
this action. Many millions of dollars have
beeninvestedbythepharmaceuticalindus-
try in developing products, the ﬁrst of
which are now in clinical practice. Many
millions of dollars therefore are now also
investedtomarketthenewagents,reminis-
cent of the period that followed the launch
of the most recent new class of drugs for
type 2 diabetes, the peroxisome prolifera-
tor–activatedreceptor-(PPAR-)agonists.
The parallels with the launch of the
PPAR- agonist and GLP-1 mimetic class
of drugs is worthy of comparison. GLP-1
andPPAR-agonisttherapiesweredevel-
oped as novel approaches for the treat-
ment of type 2 diabetes building on
elegant studies of basic physiology. There
was a clear and rational initial therapeutic
target with both classes of drugs: insulin
resistance for PPAR- agonists and en-
hanced glucose-mediated insulin secre-
tion for the GLP-1 class of drugs.
Before either class of drugs reached
market, possible additional attractive at-
tributes were identiﬁed mostly through
rodent studies. In the case of the PPAR-
agonist drugs, the most widely antici-
pated additional beneﬁt was decreased
vascular disease because of favorable ef-
fects of the drug class on risk factors for
vascular disease supported by murine
studies reporting protection against isch-
emic heart disease (3). Not until the Eu-
ropean regulatory authorities required
appropriately powered studies to demon-
strate vascular beneﬁt to support these
claims were such studies undertaken
(4,5). The results, despite optimistic in-
terpretation by the sponsors, showed lit-
tleifanycardiovascularbeneﬁtthatcould
not have been a consequence of glucose
lowering with some suggestion that the
net effects of some agents might be harm-
ful on vascular disease (6).
History may be repeating itself with
theGLP-1classofdrugs.Putativebeneﬁts
of GLP-1 mimetic therapy, in addition to
enhanced insulin secretion, have been
proposed and often arise from rodent
studies. These beneﬁts include cardiovas-
cularprotectionagainstischemiaandpre-
vention and/or reversal of the defect in
-cell mass that is characteristic of type 2
diabetes (7,8). While these attributes
wouldbehighlydesirable,thereisnocur-
rent data available to support either of
these claims in humans, and recent stud-
ies imply that the beneﬁcial effects on
-cell mass in part may be an artifact of
studies in juvenile rodents (9–11).
What is the risk proﬁle of GLP-1
drugs? Perhaps the parallel with the
PPAR- receptor agonists is again worth
considering. The receptors targeted by
each drug—the PPAR- receptor and the
GLP-1 receptor, respectively—are widely
distributed in numerous tissues with as
yet ill-deﬁned roles. As such, it is not sur-
prising when unintended consequences
ofchronicreceptoractivationemerge.Po-
tentialsignalshavealreadyemergedinthe
case of GLP-1 mimetic therapy, one is
pancreatitis (12–14) and another, which
iscurrentlyconﬁnedtorodentsstudies,is
thyroid cancer (11).
Pancreatitis ﬁrst emerged as a poten-
tial side effect of therapy with exenatide,
initially reported as case reports (12–14)
and subsequently by numerous reports
made through the U.S. Food and Drug
Administration (FDA) adverse reporting
mechanism. The Amylin Corporation’s
response to this putative link has been to
suggest that it was a consequence of guilt
by association rather than a drug effect
since pancreatitis is more common in in-
dividualswithobesityandtype2diabetes
(15). The Amylin Corporation also sug-
gested that since no mechanism is known
to link GLP-1 mimetic therapy to pancre-
atitis, the association is unlikely causal.
Pancreatitis was also seen in clinical stud-
ies of the GLP-1 agonist liraglutide (16).
More recently, the FDA has reported
more than 80 documented cases of pan-
creatitis in patients treated with sitaglip-
tin, a DPP-4 inhibitor (17). It is also
Merck’s position that the reported pan-
creatitis with sitagliptin therapy is due to
the increased risk of pancreatitis in type 2
diabetes rather than a consequence of
drug therapy (18), mimicking the Amylin
Corporation position.
In post-marketing studies sponsored
by the marketing companies, no in-
creased signal for acute pancreatitis has
beenidentiﬁed(19,20).However,thedu-
ration of treatment in those studies is typ-
ically short, the quality of the patient
follow-up is questionable, and evidence
that prescriptions were actually taken is
absent. Nonetheless, on the basis of the
available clinical information, we agree
with the conclusions of Drucker et al. (1)
that the data required to link GLP-1 ther-
apy and acute pancreatitis is currently in-
complete. However, in the context of a
new class of medical therapy, the proverb
“What you do not know cannot hurt you”
clearly does not apply. We feel that
enough preliminary evidence has accu-
mulatedtosuggestthatthereisaplausible
risk that long-term recipients of GLP-1–
basedtherapymaydevelopasymptomatic
chronic pancreatitis (Fig. 1), and worse,
subsequently a minority of individuals
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pancreatic cancer.
The incidence of both pancreatitis
and pancreatic cancer is increased in in-
dividuals with obesity and/or type 2 dia-
betes (21–23), although the underlying
mechanismsarenotwellunderstood(Fig.
1). One potential link is the frequency of
pancreatic duct replication, which is in-
creased in humans with obesity and/or
type 2 diabetes (24). It is not known why
ductal turnover is increased with obesity
and type 2 diabetes. One of the conse-
quences of chronically increased ductal
replicationcanbedistortionofsmallpan-
creatic ducts with subsequent outﬂow
obstruction of pancreatic enzymes pro-
viding a plausible mechanistic link be-
tween obesity and/or diabetes and the
increased risk for pancreatitis. Moreover,
increased ductal replication and chronic
pancreatitis are both risk factors for pan-
creatic cancer (21). Given the apparent
signal of occasional acute pancreatitis in
patients treated with GLP-1–based ther-
apy, how do we reassure ourselves that
asymptomatic chronic pancreatitis is not
also induced in some patients?
The most signiﬁcant challenge is lim-
ited access to the human pancreas. To
date there are also limited studies avail-
able in rodents. Koehler et al. (25) re-
ported no evidence of GLP-1–induced
pancreatitis based on RNA levels in mice,
but histology was not provided and num-
bers of mice in most experimental groups
(n 5) were perhaps small to conclude a
negativeﬁnding.Ontheotherhand,both
sitagliptin and exenatide have been
shown to induce pancreatitis in rats
(26,27). Sitagliptin administered to the
high-fat–fed human islet amyloid
polypeptide (HIP) rat model of type 2 di-
abetes ampliﬁed the increased pancreatic
ductcellreplicationpresentinthatmodel
(27). Moreover, sitagliptin therapy in-
duced acinar to ductal metaplasia in
30%oftreatedanimals.Acinartoductal
metaplasia follows increased ductal repli-
cation in the morphological progression
of chronic pancreatitis to pancreatic ade-
nocarcinoma (Fig. 1) (15).
Was this ﬁnding a quirk of the HIP rat
model of type 2 diabetes? Perhaps, but it is
of interest to note that increased ductal rep-
lication in the HIP rat model of type 2 dia-
betes compared with wild-type rats
reproduces that which was observed in hu-
mans with type 2 diabetes compared with
nondiabetic individuals (24). Moreover,
metformin therapy in the HIP rat had the
opposite effect of sitagliptin, decreasing the
frequency of ductal replication. Therefore,
arguably the HIP rat successfully predicts
both the increased risk of pancreatitis with
sitagliptinandthedecreasedriskofpancre-
aticcancerinindividualswithtype2diabe-
tes treated with metformin (28).
Exenatidetherapygivenover75daysto
ratsinducedlow-gradechronicpancreatitis
(26). Again, as in the case of the sitagliptin-
treated HIP rats, there was no discernable
clinical manifestation of the low-grade pan-
creatitis induced by exenatide, with the rats
innoapparentpain.IfGLP-1mimeticther-
apy with either GLP-1 mimetic therapy or
DPP-4 inhibition induces asymptomatic
chronic pancreatitis in rats, how do we
know that a similar effect is not present in
humans using these therapies? If GLP-1–
based therapy causes low chronic pancre-
atitis, why was this not established in
toxicology studies? One possibility is that
since ductal replication is increased with
obesity or type 2 diabetes (24), and GLP-1
may amplify this, studies in lean nondia-
betic animals may have had a limited pro-
pensity to GLP-1–induced pancreatitis.
Also,mosttoxicologystudiesarecarriedout
in juvenile mice in which the pancreas is
still growing. Enhanced ductal replication
underthesecircumstancesmaysimplylead
to pancreas growth as observed by Koehler
etal.(25)ratherthandistortionofthearchi-
tecture of the acinar to duct relationship,
thus predisposing to chronic pancreatitis.
While low-grade asymptomatic pan-
creatitis in and of itself as a result of GLP-
1–basedtherapywouldnotbeacausefor
major concern, the problem is that it rep-
resents a risk for pancreatic cancer (21).
The risk for developing pancreatic cancer
increases with the duration of chronic
pancreatitis(22).Becausemedicationsfor
type 2 diabetes may be taken for many
years, if GLP-1–based therapy did induce
low-grade asymptomatic pancreatitis,
there is a real concern that such a therapy
mightincreasetheriskforpancreaticcan-
cer. Even if this is a relatively small risk
(which we do not know), how many of us
practicing physicians would choose a
therapeutic strategy for ourselves with in-
sight into the potential for this risk? Since
metformin has been shown to decrease
the risk of pancreatic cancer, at the least
we would suggest that GLP-1–based
medications should be reserved for pa-
tients taking metformin.
In conclusion, we believe it is prema-
ture to conclude that the GLP-1 class of
drugshasbeenestablishedashavingagood
safety proﬁle and is appropriate for a rela-
tively early choice of therapy for type 2 di-
Figure 1—Theoretical model to explain currently available observations with increased risks for
pancreatic cancer in individuals with obesity and type 2 diabetes, a risk that is decreased by
metformin treatment and theoretically may be increased by GLP-1–based treatment.
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the GLP-1 class of drugs may induce
asymptomaticpancreatitisand,overtimein
someindividuals,inducepancreaticcancer.
Atpresent,theseconcernsarebasedonlim-
ited data. However, the implications of the
data are sufﬁciently serious that continuing
to promote this class of drugs without es-
tablishing clear experimental evidence to
permit the concern to be rejected is irre-
sponsible.Moreover,arguablypatientspre-
scribed these drugs should be made aware
of the potential risks of pancreatic cancer.
Otherwise, we collectively subscribe to the
proverb “What you do not know cannot
hurtyou”and,inthecaseofnewdrugther-
apy,thisproverbhasalreadybeenshownto
be ﬂawed.
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